CXCR4 and prostate carcinoma: The flavonol myricetin (Figure 1) could suppress the CXCL12-CXCR4 axis in human prostate cancer cells PC-3 via inhibiting the activity of Moloney murine leukemia virus 1 (PIM1) and disrupting its interaction with CXCR4, leading to a significant decrease in CXCL12-induced cell migration.